Xenon Pharmaceuticals (XENE) Return on Sales (2013 - 2025)

Xenon Pharmaceuticals (XENE) has 11 years of Return on Sales data on file, last reported at 0.47% in Q4 2025.

• On a quarterly basis, Return on Sales changed N/A year-over-year to 0.47% in Q4 2025; TTM through Dec 2025 was 0.47%, a N/A change from a year earlier, with the FY2025 full-year figure at 0.47%, changed N/A from the prior year.
• Return on Sales for Q4 2025 stood at 0.47%, down from 0.41% in the prior quarter.
• Over the last five years, Return on Sales for XENE reached as high as 0.02% in Q3 2021 and fell as low as 15.08% in Q2 2024.
• Historically, Return on Sales has averaged 1.64% across 4 years, with a median of 0.25% in 2022.
• Across the five-year window, Return on Sales tumbled 280 bps in 2022 and surged 1471 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.07% in 2021, then tumbled by 80 bps to 0.13% in 2022, then sank by 11244 bps to 15.08% in 2024, then soared by 97 bps to 0.47% in 2025.
• Per Business Quant data, the three most recent Return on Sales figures were 0.47% in Q4 2025, 0.41% in Q3 2025, and 0.37% in Q2 2025.